These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

875 related articles for article (PubMed ID: 22129252)

  • 1. Interleukin-2 and regulatory T cells in graft-versus-host disease.
    Koreth J; Matsuoka K; Kim HT; McDonough SM; Bindra B; Alyea EP; Armand P; Cutler C; Ho VT; Treister NS; Bienfang DC; Prasad S; Tzachanis D; Joyce RM; Avigan DE; Antin JH; Ritz J; Soiffer RJ
    N Engl J Med; 2011 Dec; 365(22):2055-66. PubMed ID: 22129252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
    Koreth J; Kim HT; Jones KT; Lange PB; Reynolds CG; Chammas MJ; Dusenbury K; Whangbo J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Chen YB; Avigan D; Blazar BR; Antin JH; Ritz J; Soiffer RJ
    Blood; 2016 Jul; 128(1):130-7. PubMed ID: 27073224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.
    Belizaire R; Kim HT; Poryanda SJ; Mirkovic NV; Hipolito E; Savage WJ; Reynolds CG; Fields MJ; Whangbo J; Kubo T; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Ritz J; Soiffer RJ; Koreth J
    Blood Adv; 2019 Apr; 3(7):969-979. PubMed ID: 30936057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.
    Donato V; Kim HT; Stowe P; Reynolds CG; Ritz J; Koreth J; Whangbo JS
    Front Immunol; 2022; 13():954966. PubMed ID: 36189229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.
    Saadoun D; Rosenzwajg M; Joly F; Six A; Carrat F; Thibault V; Sene D; Cacoub P; Klatzmann D
    N Engl J Med; 2011 Dec; 365(22):2067-77. PubMed ID: 22129253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
    Matsuoka K; Koreth J; Kim HT; Bascug G; McDonough S; Kawano Y; Murase K; Cutler C; Ho VT; Alyea EP; Armand P; Blazar BR; Antin JH; Soiffer RJ; Ritz J
    Sci Transl Med; 2013 Apr; 5(179):179ra43. PubMed ID: 23552371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.
    Whangbo JS; Kim HT; Mirkovic N; Leonard L; Poryanda S; Silverstein S; Kim S; Reynolds CG; Rai SC; Verrill K; Lee MA; Margossian S; Duncan C; Lehmann L; Huang J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Koreth J
    Blood Adv; 2019 Sep; 3(17):2550-2561. PubMed ID: 31471324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
    Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
    J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.
    Xie Y; Wu M; Song R; Ma J; Shi Y; Qin W; Jin Y
    Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):781-91. PubMed ID: 19727527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
    Whangbo JS; Nikiforow S; Kim HT; Wahl J; Reynolds CG; Rai SC; Kim S; Burden A; Alho AC; Lacerda JF; Alyea EP; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J; Koreth J
    Blood Adv; 2022 Nov; 6(21):5786-5796. PubMed ID: 35475885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.
    Zorn E; Mohseni M; Kim H; Porcheray F; Lynch A; Bellucci R; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):382-8. PubMed ID: 19203731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.
    Magenau JM; Qin X; Tawara I; Rogers CE; Kitko C; Schlough M; Bickley D; Braun TM; Jang PS; Lowler KP; Jones DM; Choi SW; Reddy P; Mineishi S; Levine JE; Ferrara JL; Paczesny S
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):907-14. PubMed ID: 20302964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation.
    Wolf D; Wolf AM; Fong D; Rumpold H; Strasak A; Clausen J; Nachbaur D
    Transplantation; 2007 Apr; 83(8):1107-13. PubMed ID: 17452902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
    Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
    Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
    Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
    Front Immunol; 2018; 9():3104. PubMed ID: 30733722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.
    Nikiforow S; Kim HT; Daley H; Reynolds C; Jones KT; Armand P; Ho VT; Alyea EP; Cutler CS; Ritz J; Antin JH; Soiffer RJ; Koreth J
    Haematologica; 2016 Oct; 101(10):1251-1259. PubMed ID: 27354021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.
    Pierini A; Strober W; Moffett C; Baker J; Nishikii H; Alvarez M; Pan Y; Schneidawind D; Meyer E; Negrin RS
    Blood; 2016 Aug; 128(6):866-71. PubMed ID: 27365424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease.
    Soares MV; Azevedo RI; Ferreira IA; Bucar S; Ribeiro AC; Vieira A; Pereira PNG; Ribeiro RM; Ligeiro D; Alho AC; Soares AS; Camacho N; Martins C; Lourenço F; Moreno R; Ritz J; Lacerda JF
    Front Immunol; 2019; 10():334. PubMed ID: 30894856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
    Giorgini A; Noble A
    J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease.
    Biagi E; Di Biaso I; Leoni V; Gaipa G; Rossi V; Bugarin C; Renoldi G; Parma M; Balduzzi A; Perseghin P; Biondi A
    Transplantation; 2007 Jul; 84(1):31-9. PubMed ID: 17627234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.